Topaz Therapeutics
Topaz Therapeutics is a privately held, stealth-mode San Francisco biotech founded in 2024 that is developing a platform of next-generation oncology drugs. The company has 1-10 employees, is pre-clinical with no commercial products, and is backed by Venrock.
- Company typePrivate
- Founded2024
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Topaz Therapeutics firmographics
Firmographics- Name
- Topaz Therapeutics
- Legal name
- Topaz Therapeutics
- Website
- https://topaz-tx.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Topaz Therapeutics is a privately held, stealth-mode San Francisco biotech founded in 2024 that is developing a platform of next-generation oncology drugs. The company has 1-10 employees, is pre-clinical with no commercial products, and is backed by Venrock.
- Ownership category
- akta.pro rank
Topaz Therapeutics industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Oncology & Hematology Pharmaceuticals (HLAIAAAC)
Keywords
Where Topaz Therapeutics is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Markets served
Topaz Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Marketing channels1 record
Topaz Therapeutics product offering
Product offeringCore offering
Topaz Therapeutics develops a platform of next-generation oncology drugs. Operating in stealth mode since founding in 2024, the company focuses on oncology drug discovery and the development of novel cancer therapeutics. No specific drug candidates or pipeline assets have been publicly disclosed.
Differentiator
Problem solved
Functional benefit
Products and services
- Next-Generation Oncology Drug Platform A platform-based pipeline of next-generation oncology drugs under development by Topaz Therapeutics. Targeted at pharmaceutical and biotechnology partners and ultimately cancer patients. The company is operating in stealth mode and has not disclosed specific drug candidates.
Companies that use Topaz Therapeutics
Customer profileIdeal customer profiles1 record
Topaz Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Topaz Therapeutics competitors and assessment
Company assessmentDirect peers
- Foghorn Therapeutics: Clinical-stage oncology company developing a pipeline of drugs against chromatin biology targets using a proprietary platform. Comparable as a platform-driven oncology biotech developing multiple next-generation candidates.
- Repare Therapeutics: Precision oncology company leveraging a synthetic lethality platform to develop multiple targeted cancer therapeutics. Highly comparable in modality and platform strategy.
- Insitro: Machine learning-enabled drug discovery platform developing therapies across multiple therapeutic areas including oncology. Comparable as a platform-first biotech using technology to scale candidate generation.
- Exscientia: AI-driven drug design company with active oncology pipeline and platform approach to generating multiple drug candidates. Directly comparable in business model and end markets.
- Lantern Pharma: AI-driven oncology drug discovery and development company using a data platform to identify and advance precision oncology therapeutics. Directly comparable given oncology focus and platform approach.
- Atomwise: AI-based small molecule drug discovery company with a platform used to advance multiple therapeutic programs, including oncology. Comparable platform-based discovery approach.
- Recursion Pharmaceuticals: Tech-forward drug discovery company combining high-throughput biology with machine learning to develop multiple therapeutic programs, including oncology. Highly comparable as a platform-driven biotech building a portfolio of next-generation drugs.
- Schrödinger: Physics-based computational platform company with a proprietary drug discovery pipeline spanning oncology and other areas. Comparable platform business model with partnered and wholly-owned programs.
Broad incumbents
- Isomorphic Labs: Alphabet-backed drug discovery company using deep learning to advance a portfolio of therapeutics, including in oncology. Comparable platform approach with substantially more capital and infrastructure.
Emerging players
- Owkin: AI-focused biotech combining multimodal patient data and machine learning to discover and develop therapeutics, with oncology as a focus area. Comparable as a technology-driven emerging player in oncology drug development.
Market position
Customer concentration
Topaz Therapeutics social profiles
Digital presenceTopaz Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Topaz Therapeutics leadership team
Management profileNumber of profiles
Topaz Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Topaz Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Topaz Therapeutics
What does Topaz Therapeutics do?
Topaz Therapeutics develops a platform of next-generation oncology drugs. Operating in stealth mode since founding in 2024, the company focuses on oncology drug discovery and the development of novel cancer therapeutics. No specific drug candidates or pipeline assets have been publicly disclosed.
Is Topaz Therapeutics a public or private company?
Topaz Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Topaz Therapeutics founded?
Topaz Therapeutics was founded in 2024. It employs 1 to 10 people.
Where is Topaz Therapeutics based?
Topaz Therapeutics is headquartered in San Francisco, United States, in the North America region.
Who are Topaz Therapeutics's main competitors?
Direct peers on record are Foghorn Therapeutics, Repare Therapeutics, Insitro, Exscientia, Lantern Pharma, Atomwise, Recursion Pharmaceuticals and Schrödinger. Isomorphic Labs is listed as a broad incumbent. Owkin is listed as an emerging player.
Does Topaz Therapeutics have an API?
No public API is recorded for Topaz Therapeutics.
What industry is Topaz Therapeutics in?
Topaz Therapeutics's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.